{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:57:19Z","timestamp":1777870639845,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["93-02-87-25248"],"award-info":[{"award-number":["93-02-87-25248"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1394.473"],"award-info":[{"award-number":["1394.473"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.gene.2023.147638","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:12:40Z","timestamp":1689811960000},"page":"147638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Radio-immunotherapy by 188Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphoma"],"prefix":"10.1016","volume":"882","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6458-7910","authenticated-orcid":false,"given":"Leila","family":"Nasehi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baharak","family":"Abdolhossein zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"hossein Ghahremani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.gene.2023.147638_b0005","doi-asserted-by":"crossref","first-page":"10759","DOI":"10.1016\/S0021-9258(19)50083-7","article-title":"Insulin-like growth factor I receptor gene structure","volume":"267","author":"Abbott","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2023.147638_b0010","doi-asserted-by":"crossref","unstructured":"Abdolhosseinzadeh, B., Yavari, K., Banan, M., Fallah, A. , Nasehi, L., Absalan, M., Tavoosidana, G, 2018. Lentiviral-mediated BCL2 gene knockdown using comparative microRNA adaptive shRNAs. Cell Mol Biol (Noisy le Grand) 64(11).","DOI":"10.14715\/cmb\/2018.64.11.5"},{"issue":"sup2","key":"10.1016\/j.gene.2023.147638_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21691401.2018.1449119","article-title":"A developed antibody\u2013drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line","volume":"46","author":"Abdollahpour-Alitappeh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.gene.2023.147638_b0020","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Al-Naeeb","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.gene.2023.147638_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105070","article-title":"\u03b2-radiating radionuclides in cancer treatment, novel insight into promising approach","volume":"160","author":"Asadian","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.gene.2023.147638_b0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/13543784.2018.1459560","article-title":"Ublituximab for the treatment of CD20 positive B-cell malignancies","volume":"27","author":"Babiker","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.gene.2023.147638_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0421s53","article-title":"Production and titration of lentiviral vectors","volume":"53","author":"Barde","year":"2010","journal-title":"Curr. Protoc. Neurosci."},{"issue":"5","key":"10.1016\/j.gene.2023.147638_b0040","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.gene.2023.147638_b0045","doi-asserted-by":"crossref","unstructured":"Bonavida, B., 2014. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Seminars in oncology, Elsevier.","DOI":"10.1053\/j.seminoncol.2014.08.006"},{"issue":"2","key":"10.1016\/j.gene.2023.147638_b0050","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevOncog.v17.i2.30","article-title":"Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling","volume":"17","author":"Boone","year":"2012","journal-title":"Critical Reviews\u2122 in Oncogenesis"},{"issue":"10","key":"10.1016\/j.gene.2023.147638_b0055","first-page":"3248","article-title":"Blockade of IGF\/IGF-1R signaling axis with soluble IGF-1R mutants suppresses the cell proliferation and tumor growth of human osteosarcoma","volume":"10","author":"Cao","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.gene.2023.147638_b0065","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin. Can. Res."},{"issue":"5","key":"10.1016\/j.gene.2023.147638_b0070","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nucmedbio.2008.03.001","article-title":"In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia","volume":"35","author":"De Decker","year":"2008","journal-title":"Nucl. Med. Biol."},{"issue":"6","key":"10.1016\/j.gene.2023.147638_b0080","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","article-title":"An optimized microRNA backbone for effective single-copy RNAi","volume":"5","author":"Fellmann","year":"2013","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.gene.2023.147638_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-016-0305-0","article-title":"Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma","volume":"8","author":"Flinders","year":"2016","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.gene.2023.147638_b0100","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/JME-17-0311","article-title":"40 years of IGF1: IGF1 receptor signaling pathways","volume":"61","author":"Hakuno","year":"2018","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.gene.2023.147638_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00904-3","article-title":"Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy","volume":"13","author":"Hua","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.gene.2023.147638_b0115","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/ijms21062081","article-title":"Drug resistance in non-Hodgkin lymphomas","volume":"21","author":"Klener","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2023.147638_b0120","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.gene.2023.147638_b0130","doi-asserted-by":"crossref","unstructured":"Makimoto, G., Ninomiya, K., Kubo, T., Sunami, R., Kato, Y., Ichihara, E., Ohashi, K., Rai, K., Hotta, K., Tabata, 2021. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. 51(6), 956-965.","DOI":"10.1093\/jjco\/hyab048"},{"issue":"9","key":"10.1016\/j.gene.2023.147638_b0135","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/1535370213498985","article-title":"Non-Hodgkin\u2019s B-cell lymphoma: advances in molecular strategies targeting drug resistance","volume":"238","author":"Maxwell","year":"2013","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.gene.2023.147638_b0140","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.2147\/CMAR.S243672","article-title":"Primary causes of death in patients with non-Hodgkin\u2019s lymphoma: a retrospective cohort study","volume":"12","author":"Mei","year":"2020","journal-title":"Cancer Manage. Res."},{"key":"10.1016\/j.gene.2023.147638_b0145","doi-asserted-by":"crossref","unstructured":"Molina, J.C., Shah, N.N., 2022. Monoclonal antibody-based treatment and other new agents for B-lineage acute lymphoblastic leukemia. Clin. Manage. Acute Lymphoblast. Leukemia, Springer, 295-328.","DOI":"10.1007\/978-3-030-85147-7_13"},{"issue":"2","key":"10.1016\/j.gene.2023.147638_b0150","doi-asserted-by":"crossref","DOI":"10.14715\/cmb\/2017.63.2.9","article-title":"Stable silencing of IGF1R using Lentiviral-mediated shRNA in HEK293T cells","volume":"63","author":"Nasehi","year":"2017","journal-title":"Cell Mol Biol (Noisy le Grand)"},{"key":"10.1016\/j.gene.2023.147638_b0155","doi-asserted-by":"crossref","unstructured":"Ngo, M.-H.T., Peng, S.-W., Kuo, Y.-C., Lin, C.-Y., Wu, M.-H., Chuang, C.-H., Kao, C.-X., Jeng, H.-Y., Lin, G.-W., Ling, T.-Y.J.C., 2021. A yes-associated protein (YAP) and insulin-like growth factor 1 receptor (IGF-1R) signaling loop is involved in sorafenib resistance in hepatocellular carcinoma. 13(15), 3812.","DOI":"10.3390\/cancers13153812"},{"issue":"8","key":"10.1016\/j.gene.2023.147638_b0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/cells8080895","article-title":"Therapeutic targeting of the IGF axis","volume":"8","author":"Osher","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.gene.2023.147638_b0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"10","key":"10.1016\/j.gene.2023.147638_b0170","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.gene.2023.147638_b0175","unstructured":"Sapkota, S., Shaikh, H., 2020. Non-Hodgkin Lymphoma. StatPearls [Internet]."},{"issue":"6","key":"10.1016\/j.gene.2023.147638_b0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.gene.2023.147638_b0185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11899-019-00542-8","article-title":"Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies","volume":"14","author":"Torka","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.gene.2023.147638_b0190","doi-asserted-by":"crossref","unstructured":"Tsai, P.-C., Nayeen, B., Olejniczak, S., Hernandez-Ilizaliturri, F., Czuczman, M., 2010. Regulation of CD20 in rituximab-resistant cell lines (RRCL) and B-cell non-Hodgkin's lymphomas (NHL). J. IMMUNOL., AACR.","DOI":"10.4049\/jimmunol.184.Supp.88.18"},{"key":"10.1016\/j.gene.2023.147638_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctro.2017.09.006","article-title":"The impact of the IGF-1 system of cancer cells on radiation response \u2013 an in vitro study","volume":"7","author":"Venkatachalam","year":"2017","journal-title":"Clin. Translat. Radiat. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.gene.2023.147638_b0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11010-010-0453-2","article-title":"Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo","volume":"341","author":"Wang","year":"2010","journal-title":"Mol. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.gene.2023.147638_b0205","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/13543784.2019.1694660","article-title":"Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy","volume":"28","author":"Werner","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.gene.2023.147638_b0210","doi-asserted-by":"crossref","unstructured":"Yang, C., Zhang, Y., Segar, N., Huang, C., Zeng, P., Tan, X., Mao, L., Chen, Z., Haglund, F., Larsson, O.J.O.R., 2021. Nuclear IGF1R interacts with NuMA and regulates 53BP1-dependent DNA double\u2011strand break repair in colorectal cancer 46(2), 1\u201311.","DOI":"10.3892\/or.2021.8119"},{"issue":"1","key":"10.1016\/j.gene.2023.147638_b0215","first-page":"41","article-title":"Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy","volume":"15","author":"Yuan","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.gene.2023.147638_b0220","doi-asserted-by":"crossref","unstructured":"Zhang, M., Li, Z., Liu, X.J.A.P.J.o.C.P.A., 2021. MiR-98-5p\/IGF2 axis influence herceptin sensitivity through IGF1R\/HER2 heterodimer formation and AKT\/mTOR signal pathway in HER2 positive breast cancer. 22(11), 3693.","DOI":"10.31557\/APJCP.2021.22.11.3693"},{"issue":"9","key":"10.1016\/j.gene.2023.147638_b0225","first-page":"681","article-title":"Mechanism and treatment of rituximab resistance in diffuse large B-cell lymphoma","volume":"19","author":"Zou","year":"2019","journal-title":"Curr. Canc. Drug Targets"},{"issue":"5","key":"10.1016\/j.gene.2023.147638_b0060","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3892\/or.2012.1964","article-title":"Lentivirus-mediated short-hairpin RNA targeting IGF-1R inhibits growth and lymphangiogenesis in breast cancer","volume":"28","author":"Chen","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.gene.2023.147638_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fendo.2015.00059","article-title":"Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation","volume":"6","author":"Farabaugh","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.gene.2023.147638_b0090","doi-asserted-by":"crossref","unstructured":"Fuertes, T., Ramiro, A.R., de Yebenes, V.G., 2020. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. Trends in Immunology.","DOI":"10.1016\/j.it.2020.08.006"},{"key":"10.1016\/j.gene.2023.147638_b0095","doi-asserted-by":"crossref","unstructured":"Fuertes, T., Ramiro, A. R., de Yebenes, V.G.J.T.i.I., 2020. miRNA-based therapies in B cell non-Hodgkin lymphoma. 41(10): 932-947.","DOI":"10.1016\/j.it.2020.08.006"},{"issue":"20","key":"10.1016\/j.gene.2023.147638_b0105","first-page":"4885","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.gene.2023.147638_b0125","first-page":"1332","article-title":"Insulin-like growth factor-1 receptor knockdown enhances radiosensitivity via the HIF-1\u03b1 pathway and attenuates ATM\/H2AX\/53BP1 DNA repair activation in human lung squamous carcinoma cells","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol. Lett."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111923004791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111923004791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:28:43Z","timestamp":1777566523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111923004791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":45,"alternative-id":["S0378111923004791"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2023.147638","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radio-immunotherapy by 188Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphoma","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2023.147638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"147638"}}